Cellosaurus logo
expasy logo

Cellosaurus 501-mel (CVCL_4633)

[Text version]
Cell line name 501-mel
Synonyms 501-MEL; 501 mel; 501 Mel; 501Mel; 501mel; 501MEL; 501; Mel 501; Mel501; MEL501; Me 501; Me-501; Me501
Accession CVCL_4633
Secondary accession CVCL_C608
Resource Identification Initiative To cite this cell line use: 501-mel (RRID:CVCL_4633)
Comments From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
Microsatellite instability: Stable (MSS) (PubMed=23671654).
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445).
  • Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=23851445).
  • Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Unspecified (PubMed=23851445).
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
HLA typing Source: PubMed=15592718
Class I
Class II

Source: PubMed=25960936
Class I
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Not specified.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_A1DM ! 501-EBV
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ESTDAB


Run an STR similarity search on this cell line

PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225
Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R., Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K., Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.
Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
J. Immunol. 153:1225-1237(1994)

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A
Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A., Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
Int. J. Cancer 80:781-790(1999)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=20149136; DOI=10.1111/j.1755-148X.2010.00685.x
Halaban R., Zhang W., Bacchiocchi A., Cheng E., Parisi F., Ariyan S., Krauthammer M., McCusker J.P., Kluger Y., Sznol M.
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Pigment Cell Melanoma Res. 23:190-200(2010)

PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958
Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=30674989; DOI=10.1038/s41388-018-0640-2
Mancuso P., Tricarico R., Bhattacharjee V., Cosentino L., Kadariya Y., Jelinek J., Nicolas E., Einarson M., Beeharry N., Devarajan K., Katz R.A., Dorjsuren D.G., Sun H.-M., Simeonov A., Giordano A., Testa J.R., Davidson G., Davidson I., Larue L., Sobol R.W., Yen T.J., Bellacosa A.
Thymine DNA glycosylase as a novel target for melanoma.
Oncogene 38:3710-3728(2019)

Cell line databases/resources CGH-DB; 9296-4
IGRhCellID; 501Mel
Anatomy/cell type resources BTO; BTO:0002956
Encyclopedic resources Wikidata; Q54603677
Gene expression databases GEO; GSM188239
GEO; GSM188269
GEO; GSM188328
GEO; GSM433918
GEO; GSM555120
GEO; GSM555174
Polymorphism and mutation databases Cosmic; 686481
Cosmic; 876680
Cosmic; 905210
Cosmic; 1197392
Cosmic; 1238106
Cosmic; 1458962
Cosmic; 1559440
Cosmic; 2159451
Cosmic; 2163827
Cosmic; 2440478
Progenetix; CVCL_4633
Entry history
Entry creation04-Apr-2012
Last entry update21-Mar-2023
Version number22